- Discover new methods for managing clinical next-gen data with insights from Pfizer, Boston Children’s Hospital and AstraZeneca - Uncover and critique the latest technologies out there for you to use in clinical trials. Mayo Clinic, Merck and Harvard Medical School let you into their trade secrets - Hear the genomics strategies that Roche, Millennium and Regeneron are using for discovery and validation of clinically actionable biomarkers -Bristol-Myers Squibb, Takeda and Partners Healthcare the role that NGS can play when implementing an effective strategy in the lab to speed up CDx development - Learn how to integrate molecular details into medical decision making, with fresh data from Washington University School of Medicine and Genzyme

1. Book early and save up to $500
“That was the best
event I have ever
attended…You have a
committed customer
from this point onwards”
Sanofi
28th-30th January 2014, Boston
Control Your Next-Gen Data
Discover Clinically Actionable Biomarkers
Personalize Medical Care
22 Expert Speakers Including:
Nadeem Sarwar
Senior Director, Worldwide
Clinical Research
Pfizer
Rong Chen
Director, Clinical Research
Mount Sinai School of
Medicine
Sanjay Rakhade
Director, Global Clinical
Development
Genzyme
Oscar Puig
Biomarker & Experimental
Medicine Leader
Roche
Birgit Funke
Director, Clinical R&D
Laboratory for Molecular
Medicine
Partners Healthcare
Tel: +44 (0)203 141 8707
Email: join@hansonwade.com
www.clinicalgenomics-usa.com

2. Boston
28th-30th January 2014
From past attendees
A Welcome From The Chairman
Dear Colleague,
Genomic information is changing and challenging the practice of
medicine…
Clinical genomics. Many from pharma and research institutes alike
are calling it a ‘genetics revolution’. The era of personalized genomic
health that is no longer simply a pipe-dream.
You know sequencing isn’t a painless process. But there are
solutions out there. Clinical Genomics 2014 will uncover success
stories from the pioneers selecting the right drug for the patient
based on their genomic targets.
Why do I think you should attend? Just a few reasons…
1. You can discover novel methods for cracking the clinical data
bottleneck with new data from Pfizer, Boston Children’s
Hospital and AstraZeneca
“This is the best conference I
have ever gone to…I have already
recommended people in my group
to go next year.”
AVEO
“I thought that conference was
well organized, sessions were well
planned and we had a good mix of
academic & pharma speakers. So
overall, the conference was a great
success.”
GSK
2. Find out what technologies are out there for you to use in clinical
trials. Mayo Clinic, Merck and Harvard Medical School let you
into their trade secrets…
3. You will hear the strategies that Roche, Millennium and
Regeneron use for their biomarker discovery, development and
delivery in the clinic
“I enjoyed the meeting very much.
The size was ideal to encourage
communication and networking.”
4. Bristol-Myers Squibb, Takeda and Partners Healthcare will help
you explore the clinical diagnostic landscape, and the role that NGS
can play when implementing an effective strategy in the lab
5. Networking! Benefit from the unique format of Clinical
Genomics 2014 and take part in the interactive workshops, speed
networking and round table discussions available to make the
most of your time
Complete Genomics
“All very motivated, well spoken
speakers. Very good presentations
overall. Topics were well selected.”
Whatever your motivations, Clinical Genomics 2014 will give you
clarity on exactly how NGS can be applied in a clinical setting.
Integrating molecular details into day-to-day patient decision-making
processes.
We need to start asking the right questions from clinical data: will
it help in creating new drug discovery programs? Will it help with
biomarker discovery? Will it help with patient stratification?
There is a huge translational gap that needs to be closed if we are
to make any headway. If we want to get this right, we need to break
the silos and start communicating.
Actelion
“It exceeded my expectations. The
talks were high quality and the
interaction among participants was
excellent.”
Genentech
Best wishes and hope to see you in Boston.
Seth Crosby
Director, Partnerships & Alliances
Washington University School
of Medicine
Chairman of Clinical Genomics 2014
Tel: +44 (0)203 141 8707
Email: join@hansonwade.com
“Whoever designed the structure
of this summit deserves a credit.
Lots of thought has been put in to
organising and selection of topics.
Kudos to the organizing team.”
Coldstream Laboratories
www.clinicalgenomics-usa.com

3. Boston
28th-30th January 2014
Speakers
Kelci Miclaus
Research Statistician Developer
JMP Life Sciences, SAS
Association
Brian Dougherty
Translational Genomics Lead
AstraZeneca
Catherine Brownstein
Research Sequencing
Project Manager
Boston Children’s Hopital
Jun Li
Senior Research Investigator
Bristol-Myers Squibb
Sanjay Rakhade
Director, Global Clinical
Development
Genzyme
Birgit Funke
Director, Clinical R&D Laboratory
for Molecular Medicine
Harvard Medical School
Joe Monforte
Independent Consultant
David Smith
Professor, Laboratory of
Medicine & Pathology
Mayo Clinic
Ken Chang
Clinical Assay Development &
Outsourcing Lead
Merck
Saumya Pant
Clinical Development
Research Fellow
Merck
Sunita Badola
Senior Manager, Translational
Medicine
Millennium
Rong Chen
Director, Clinical Genome
Informatics
Mount Sinai School of Medicine
Matthew Lebo
Assistant Laboratory Director
Partners Healthcare
Mollie Roth
Managing Partner
PGx Consulting
Pia Gargiulo
Independent Consultant
Nadeem Sarwar
Senior Director, Worldwide
Clinical Research, Pfizer
Mitchell Martin
Director, Predictive Medicine,
Oncology
Regeneron
Oscar Puig
Biomarker & Experimental
Medicine Leader
Roche
Justin Klekota
Scientist II
Takeda
Shashikant Kulkarni
Head, Clinical Genomics
Washington University
School of Medicine
“You did a great job bringing together some bright minds. I got
two full days of exposure to information I will benefit from.”
Seth Crosby
Director, Partnerships & Alliances
Washington University School
of Medicine
Tel: +44 (0)203 141 8707
Integrated DNA Technologies
Email: join@hansonwade.com
www.clinicalgenomics-usa.com

4. Boston
28th-30th January 2014
Conference Workshops
Workshop A: Incorporating NGS into Companion Diagnostics
Date: 28th January 2014, Time: 9 - 12
As the costs of NGS decreases, the opportunity to use personalized genomics
in clinical studies has become more accessible than ever. And the development of
genomic sequencing methods could help to rapidly identify genetic alterations which may
serve as targets for new diagnostic tests.
Workshop Leaders
Matthew Lebo
Assistant Laboratory Director,
Whole Genome Sequencing
Partners Healthcare Center for
Personalized Genetic Medicine
But how can we ensure we are maximizing the returns on investment for these
technologies and achieving the best results we can for patient selection?
This session will explore how you can realistically make NGS an integral part of your
personalized medicine strategies:
•
Find out how identify and evaluate cancer-causing mutations using sophisticated
sequencing technologies
•
Explore the possibilities of NGS to identify new targets for clinically relevant
companion diagnostic tests
•
As a director in a clinical diagnostics laboratory,
Matt is responsible for the interpretation and
reporting of large gene panel tests – with a special
focus in cardiomyopathy – and the development of
next-generation sequencing tests, including clinical
genome/exome sequencing.
Evaluate what NGS technologies and services are available to you to successfully to
optimize your patient population approaches
“Excellent cross section of core science, regulatory, commercialization
and project management from both pharma and diagnostic
companies. Very educational”
Eli Lilly
Workshop B: Next Generation Sequencing Platforms for the Clinic
Date: 28th January 2014, Time: 12.30 - 3.30
Next Generation sequencing is poised to make a significant impact upon clinical practice. While
the first clinical applications of NGS will most probably be small gene panels, within the next
few years this technology will become integrated into routine clinical practice.
This will still include the small gene panels, but will also include, much larger gene panels
(such as the one that is used by Foundation Medicine for Cancer Treatment), whole exome
sequencing, whole genome sequencing, transcriptome sequencing and maybe even
methylation sequencing…
Each of these different applications has its own unique set of challenges, suggesting that there
may not be a single sequencing platform that can meet all these needs.
This workshop will be an enlightening introduction to NGS technology – present and future.
What should you use? Why should you use it?
Attend this session for…
•
A brief history of NGS: Where have we come from, and where are we going?
•
A review of each of the available and soon to be available platforms: their strengths, their
weaknesses, and which clinical application each is best suited for
•
Workshop Leaders
David Smith
Professor, Laboratory of
Medicine Pathology
Mayo Clinic
The laboratory of David Smith uses the most cuttingedge genomic technologies to better understand the
molecular alterations that underlie cancer development.
David is also the chairman of the Technology Assessment
Committee, which works for the Center for Individualized
Medicine at Mayo Clinic. The goal of this committee is to
evaluate new technologies that could have a significant
impact on research and its clinical translation.
The clinical vision for sequencing platforms
•
As a member of the IT team at Partners, Matt also
works on the development of GeneInsight Suite,
an innovative software platform for molecular
laboratories, clinics, and EHR systems that manages
variant, gene, and disease annotations and the
integration of that information into patient reports.
A presentation from laboratories already using NGS as a routine part of clinical practice
Perhaps the most exciting technology has been the
recent advancements in DNA sequencing, which now
make it possible to completely sequence a person’s
entire genome for just a few thousand dollars.
See next page for more conference workshops
Tel: +44 (0)203 141 8707
Email: join@hansonwade.com
www.clinicalgenomics-usa.com

5. Boston
28th-30th January 2014
Workshop C: Issues with Developing and Implementing NGS
Technologies: A Lifespan Review
Date: 28th January 2014, Time: 4 - 7
Workshop Leaders
As we move closer towards integrating Next Gen Sequencing into clinical practice, we
continue to face numerous hurdles across the developmental lifespan from early RD
through application in clinical trials through to understanding how to drive commercial
success of these tests in the targeted therapy space.
Mollie Roth
Managing Partner
PGx Consulting
This workshop will address key issues across this lifespan, including:
•
The underlying data, how it will be maintained and updated and who owns it
•
The regulatory impediments based upon the constantly shifting data underlying NGS
tests
•
Internal barriers to success of NGS inherent in the pharma and diagnostic business
models
•
Obtaining reimbursement for tests that potentially provide broader data than strictly
required to guide use of specific drugs
•
Educating physicians and patients about NGS and what it means to their practice and
health
Interactive discussions will be driven by use of realistic hypotheticals designed to
demonstrate tangible issues and address specific concerns in the NGS space.
Joe Monforte
Independent Consultant
Joe is a leading expert in genomics and molecular
analysis, with an emphasis on PCR and multiple
generations of sequencing. His experience ranges from
molecular chemistry and analytical platform development,
through full-scale diagnostic development and
deployment in the clinical setting.
Pia Gargiuli
Independent Consultant
Join our Linkedin group and enjoy
discussions with the online community
in the run up to the meeting. Just search
Linkedin groups for Clinical Genomics
Join the discussion and
Tweet about the event using
#ClinicalGenomics
An attorney by training, Mollie is the Managing Partner
of PGx Consulting, which provides customized,
personalized medicine specific business services to the
pharmaceutical, biotech and diagnostic industries in the
personalized medicine space.
Pia has led teams in the novel development, deployment,
and delivery of companion diagnostic programs
focusing on the broad technical utility and uptake of
commercialization models for both the pharmaceutical
and diagnostic industries. She has over 15 years’
experience in industry and academia with a strong focus
in Oncology.
Media Partners
Tel: +44 (0)203 141 8707
Email: join@hansonwade.com
www.clinicalgenomics-usa.com

6. Boston
Day 1 - 29th January 2014
Clinical Genomics in the Age of Next Generation Sequencing
08.00 Registration Breakfast
08.50 Chair’s Opening Remarks
Genomics in the Clinic: Where are we now, and where
do we want to be?
Seth Crosby, Director, Partnerships Alliances, Washington
University School of Medicine
High-Throughput Genomic Technology in Research and
Clinical Trials: What Choice is the Right Choice?
09.00 The HPV Epidemic: Understanding it’s Role in the
Evolution of Oropharyngeal Cancer
• How HPV is responsible for the explosion in the cases of
OPSCC in spite of decreased incidence of smoking in the
United States
• How the role of HPV in the development of OPSCC is
distinct from its’ well characterized role in cervical cancer
• The power of mate-pair sequencing to determine the
precise status of HPV in OPSCC
David Smith, Professor, Laboratory of Medicine
Pathology, Mayo Clinic
09.30 From Genes to Genomes - Implementing NGS in the Clinic
• Discussing how next generation sequencing technologies
have revolutionized diagnostic testing
• Benefits and challenges of current NGS tests - gene
panels and exome/genome
• Impact of expanded testing on result interpretation variant assessment as the new bottle neck in genomics
Birgit Funke, Director, Clinical RD Laboratory for
Molecular Medicine, Harvard Medical School
10.00 Speed Networking
11.00 Morning Refreshments
Cracking the Clinical Data Interpretation Bottleneck
for Medical Decision Making
11.30 Implementation and Integration of NGS Services at
Boston Children’s Hospital
• New initiatives at Boston Children’s Hospital to increase
the clinical utility of NGS data
• Faster and more accurate diagnosis through NGS results
in targeted prescribing and increased possibilities for
investigational therapies
• Case studies from the past 12 months demonstrating how
BCH has reduced the obstacles between rare disease
research and clinical discovery
Catherine Brownstein, Research Sequencing Project
Manager, Boston Children’s Hospital
12.00 PANEL SESSION: Sequencing is the Easy Bit. But now
how do we Make Sense of the Data?
• Solving the clinical puzzle: a discussion of novel
computational techniques for implementing patient
selection and diagnostic strategies
• Whole genome studies and translational bioinformatics:
what does all this data mean?
(Moderator) Catherine Brownstein, Research Sequencing
Project Manager, Boston Children’s Hospital; Nadeem
Sarwar, Senior Director, Worldwide Clinical Research,
Pfizer; Jun Li, Senior Research Investigator, Bristol-Myers
Squibb; David Smith, Professor, Laboratory of Medicine
Pathology, Mayo Clinic
Tel: +44 (0)203 141 8707
12.30 Clinically Actionable Results through Discovery and
Prediction
• Next Generation Sequencing Whole-Genome, Exome,
RNA-Seq analysis
• Integrated genomic analysis
• Biomarker discovery
• Clinical subgroup analysis
Kelci Miclaus, Research Statistician,
JMP Life Sciences, SAS Association
12.45 Networking Lunch
2.00 Driving Personalized Medicine and Clinical Diagnosis
Using Genome Sequencing, Exome Sequencing and
Integrative Genomics
• Applying data from whole WES and WGS for diagnosis
and decision making in a clinical lab
• Integrating and translating various molecular
measurements in the public repositories into biomarkers
for the diagnosis of disease
• Discovery of causal variants, pathway, and mechanisms
to illustrate human disease through integrative genomic
Rong Chen, Director, Clinical Genome Informatics, Mount
Sinai School of Medicine
A New Paradigm for Drug Discovery: Integrating Clinical
Data for Novel Drug Discovery Programs
2.30 Catalyzing the Translation of Genetic Signals into
Therapeutic Targets
• The evolution of the role of human genetics and related
sciences in medicines development: from traditionally
reserved for late-phase “pharmacogenetic exploration” to
application across all stages of the pipeline
• Discussing the role of the integration of different layers of
robust human biology data
• Catalyzing translational value of human genetics “from
insight to impact” to necessitate multi-disciplinary and
multi-sector collaboration
Nadeem Sarwar, Senior Director, Worldwide Clinical
Research, Pfizer
3.00 Afternoon Refreshment Break
3.30 Closing the Translational Gap: Using Patient Data to
Educate and Guide us in Early Discovery Research
• Setting up a center for genomics data that ensures
integrated data for laboratory management
• A comprehensive genetics and functional genomics
approach to the annotation of genomes, and applying
such methods to the validation of targets
Sanjay Rakhade, Director, Global Clinical Development,
Genzyme
4.00 Regulatory Roundtable Discussion Forum
An exclusive session led by the speakers but with the
content directed by you. This is the opportunity for
leaders in the clinical genomics field to sit and discuss,
off the record, what can be done to overcome the
crippling regulatory hurdles. The roundtable forum
agenda will be made up of queries submitted by the
attendees of the meeting.
5.00 Regulatory Roundtable Presentations
5.30 Chair’s Closing Remarks
5.45 Networking Drinks Reception
Email: join@hansonwade.com
www.clinicalgenomics-usa.com

7. Boston
Day 2 - 30th January 2014
Making the Case for Genomics in Clinical Medicine
08.00 Registration Breakfast
08.50 Chair’s Opening Remarks
Let’s Not Reinvent the Wheel with Clinical Genomics…
What can we take from what’s been done before?
Seth Crosby, Director, Partnerships Alliances,
Washington University School of Medicine
Discover, Development Delivery of Clinically
Actionable Biomarkers
11.30 PANEL SESSION: Is Personalized Medicine a Future
Reality? Harnessing Clinical Data for Informed Patient
Stratification
(Moderator) Oscar Puig, Biomarker Experimental
Medicine Leader, Roche; Mitchell Martin, Director,
Predictive Medicine, Oncology, Regeneron; Justin
Klekota, Scientist II, Takeda; Jun Li, Senior Research
Investigator, Bristol-Myers Squibb
12.00 Lunch Networking
09.00 Establishing the Routine: Validating Biomarkers Through
Clinical Research to Translate and Integrate into Clinical
Practice
• What stage have we got to in the clinic? Applying NGS for
biomarker development and subject stratification
• Securing strong predictive biomarkers to compliment
products translating into clinical development
• Incorporating predictive biomarkers into early stage RD
to ensure each clinical candidate has a complimentary
biomarker when it reaches the clinic
Brian Dougherty, Translational Genomics Lead,
AstraZeneca
1.30 Implementation of Genome Sequencing in a Clinical
Diagnostic Laboratory
• Identifying the appropriate datasets and approaches to
validate genome sequencing pipelines
• Explaining important concepts that should be considered
when developing clinical reports based upon the results
of genome sequencing
• Detailing our experiences offering genome sequencing in
clinical care, including our support of the MedSeq project
Matthew Lebo, Assistant Laboratory Director, Partners
Healthcare
09.30 Clinical Genomics in Drug Response and Resistance
• How do we use genomic tools to understand drug
response and resistance in clinical trials?
• What clinical samples can be used? How do we get
them?
• What are the limitations?
Oscar Puig, Biomarker Experimental Medicine Leader,
Roche
2.00 Application of Novel Technologies for Better Patient
Selection Strategies in Clinical Trials
• Using next generation sequencing and microarray for
comprehensive characterization of cancer tumors
• What challenges are presented by method of sample prep
and preservation?
Sunita Badola, Senior Manager, Translational Medicine,
Millennium
Integrated Clinical Genomics: New Horizons for
Diagnostics and Biomarker Discovery
10.00 Next-Generation Clinical Genomic Profiling to Aid
Clinical Diagnosis and Predict Outcomes
• Design, validation and implementation of a
comprehensive mutation analysis of multiple cancer
genes
• Constantly improving cost-effective, clinically actionable
diagnostic markers
• Unveiling key genomic drivers, prognostic and diagnostic
indicators in cancer
Shashi Kulkarni, Head, Clinical Genomics, Director,
Cytogenomics and Molecular Pathology,
Washington University School of Medicine
10.30 Morning Refreshment Break
11.00 Development and Validation of a Clinical Trial Patient
Stratification Assay that Interrogates 27 Mutation Sites
in MAPK Pathway Genes
• Overcoming the technical challenges in the process of
developing and validating patient stratification assays
• Using Next Generation sequencing to resolve discordant
calls between the SNPE mutation assay and Sanger
sequencing
Ken Chang, Clinical Assay Development Outsourcing
Lead, Merck
Tel: +44 (0)203 141 8707
2.30 Afternoon Refreshment Break
Medically Actionably Genomics: Clearing the Road to
Routine Whole Genome Sequencing
3.00 Clinical Genomic Biomarker Assay Development:
Technologies and Issues
• Considerations in planning a clinical NGS based assay
• Challenges for NGS based assay translation to CDx
• Promise for the future with NGS clinical trial assays:
no more “business as usual”
Saumya Pant, Clinical Development Research Fellow,
Merck
3.30 PANEL SESSION: Incidental Findings or Good Medical
Practice? Patient Choice, Patient Preference and Lab
Responsibility
(Moderator) David Smith, Professor, Laboratory of
Medicine Pathology, Mayo Clinic; Sunita Badola, Senior
Manager, Translational Medicine, Millennium; Nadeem
Sarwar, Senior Director, Worldwide Clinical Research,
Pfizer
Matthew Lebo, Assistant Laboratory Director, Partners
Healthcare
4.00 Chair’s Closing Remarks
Email: join@hansonwade.com
www.clinicalgenomics-usa.com

8. Boston
28th-30th January 2014
“Good meeting – great
selection of speakers. The
speed networking was
very effective to connect
with all participants.”
PwC
Spotlight Partner
JMP® Genomics and JMP® Clinical software from SAS are
customized for dynamic visualization of life sciences data, fueling
discoveries from the earliest stages of molecular research to the
final phases of drug development. They integrate powerful SAS®
Analytics with the graphical flexibility of JMP, putting multifaceted analysis options into
the hands of all users, regardless of their statistical savvy.
Why Sponsor Clinical Genomics 2014?
As a service provider in this space you will be well aware that the field is expanding. Clinical Genomics 2014 is the
opportunity to get a foot in the door, stay ahead of your competitors and present your capabilities to a captive audience
of senior power buyers who are already primed to invest in this space.
It’s all about bringing together the leading scientists who are heading up the world’s most innovative and advanced
clinical genomics programs to make progress happen.
Clinical Genomics 2014 provides a unique platform to access these decision makers; this forum doesn’t exist anywhere
else in the world.
Imagine yourself presenting to a room full of drug developers and demonstrating how your technology and approach will
help them apply NGS in a meaningful way to deliver commercial results. At Clinical Genomics 2014 you can position
your company as the partner of choice.
What Options are Available?
Who Should Sponsor?
Scientific Presentation: Demonstrate thought
leadership and present your message through
a scientific presentation built into the agenda.
Private Lunch: Hosting a lunch with a pre-selected
group of attendees is an excellent way to interact
and impress prospective clients. This hugely personal
networking opportunity gives you one-to-one access
with a hand-picked audience selected by you.
Exhibition Booth: The best opportunity to showcase
your company’s products, services and technology.
All booths are in a central location, surrounded by
all the networking functions and are ideally placed to
allow you to interact with the attendees searching for
solutions.
Innovation Panel: Ideal for up-and-coming
companies who are looking to showcase their
solutions. This is an excellent way to drive customers
to your meeting area where relationships can be further
forged or strengthened.
Bespoke sponsorship packages are available – we
would be happy to discuss your specific requirements.
Tel: +44 (0)203 141 8707
Email: join@hansonwade.com
Sequencing Companies
Genomic CROs
Genomic Data Storage Analysis Software Companies
Diagnostics Developers
Target Discovery Companies
For information on sponsorship,
please contact Diane McKenna at:
sponsor@hansonwade.com or call
+44 (0) 20 3141 8746
If you have any questions about the program, contact:
izzy.scott-moncrieff@hansonwade.com
For media and marketing queries, contact:
craig.love@hansonwade.com
www.clinicalgenomics-usa.com

9. Boston
28th-30th January 2014
SPX
Priority code:
Event Prices
Register
Tel: +1 (212) 357 5898
Email: info@hansonwade.com
Package
Register before
Friday 6th December
2013*
Standard
Prices*
2 day conference
+ 3 workshops
$3698
(save $500)
$3898
(save $300)
Team Discounts
2 day conference
+ 2 workshops
$3197
(save $400)
$3597
• 10% discount – 3 delegates
• 15% discount – 4 delegates
• 20% discount – 5 or more delegates
2 day conference
+ 1 workshop
$2698
(save $300)
$2998
Please note that discounts are only valid when three or more
delegates from one company book and pay at the same time.
2 day conference
$2199
(save $200)
$2399
Workshops (each)
$599
$599
Mail: Hanson Wade
304 Park Avenue South, 11th Floor
New York, NY 10010
Venue and Accommodation
Hyatt Regency Boston
1 Ave De Lafayette, Boston, MA 02111, United States
Accommodation
Overnight accommodation is not included in the registration
fee, however accommodation options will be sent out with your
confirmation email upon registering.
Please select your choice of Workshop:
A
B
C
There is a 40% discount available for not-for-profit institutions.
For more information please email: register@hansonwade.com
*All discount offers (including team discounts) require payment at the time of registration to receive any discount. ‘Early Bird’ discounts require payment at time of registration and
on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer. The conference fee includes lunch, refreshments and course
documentation. The fee does not include travel or hotel accommodation.
Delegate Details
Title: Forename:
Surname:
Job Title:
Company/Organization:
Email:
Direct Manager:
Address:
Country:
Direct Telephone:
Direct Fax:
Mobile:
Switchboard:
Postcode:
Signature:
Date:
Payment Details
Number of delegates:
Amount: $
Conference Documentation:
Card No:
Credit Card:
Visa
Valid from:
/
Mastercard
Amex
Expiry Date:
/
Cardholders name:
Signature:
Date:
Card billing address:
TERMS CONDITIONS
Changes to Conference Agenda: Hanson Wade reserves the right to
postpone or cancel an event, to change the location or alter the advertised
speakers. Hanson Wade is not responsible for any loss or damage or costs
incurred as a result of substitution, alteration, postponement or cancellation
of an event for any reason and including causes beyond its control
including without limitation, acts of God, natural disasters, sabotage,
accident, trade or industrial disputes, terrorism or hostilities.
Data Protection: The personal information shown and/or provided by you
will be held in a database. It may be used to keep you up to date with
developments in your industry. Sometimes your details may be obtained or
made available to third parties for marketing purposes. If you do not wish
your details to be used for this purpose, please write to: Database Manager,
Hanson Wade, Charter House, 13-15 Carteret Street, London SW1H 9DJ
Hanson Wade Limited. Registered in England Wales. Company No: 6752216
Tel: +44 (0)203 141 8707
Email: join@hansonwade.com
www.clinicalgenomics-usa.com
Code: 4095
Full payment is due on registration. Cancellation and Substitution Policy:
Cancellations must be received in writing. If the cancellation is received more
than 14 days before the conference attendees will receive a full credit to
a future conference. Cancellations received 14 days or less (including the
fourteenth day) prior to the conference will be liable for the full fee.
A substitution from the same organization can be made at any time.